Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 96.73M P/E - EPS this Y 8.40% Ern Qtrly Grth -
Income -27.62M Forward P/E -2.08 EPS next Y 26.10% 50D Avg Chg -29.00%
Sales 8.55M PEG -0.06 EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 5.61 EPS next 5Y 15.00% 52W High Chg -64.00%
Recommedations 2.20 Quick Ratio 1.15 Shares Outstanding 29.83M 52W Low Chg 19.00%
Insider Own 6.35% ROA -43.79% Shares Float 28.07M Beta -
Inst Own 23.44% ROE -138.93% Shares Shorted/Prior 1.04M/0.99M Price 3.52
Gross Margin 79.91% Profit Margin - Avg. Volume 214,420 Target Price 6.75
Oper. Margin -234.32% Earnings Date May 6 Volume 205,497 Change -1.68%
About DURECT Corporation

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DURECT Corporation News
03/27/24 Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
03/27/24 DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/20/24 DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
03/04/24 DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
02/29/24 Pacira (PCRX) Matches Q4 Earnings Estimates
02/07/24 DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
11/14/23 Q3 2023 DURECT Corp Earnings Call
11/13/23 DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
11/13/23 Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
11/09/23 DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
11/07/23 DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
10/19/23 These 2 ‘Strong Buy’ Penny Stocks Have Massive Upside Potential, Says Oppenheimer
10/02/23 3 Promising Biotech Stocks That Will Make Early Investors Rich
09/07/23 DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
08/31/23 DURECT Corporation Announces Presentations in Upcoming Investor Conferences
08/14/23 10 Oversold Penny Stocks To Buy
08/10/23 Q2 2023 DURECT Corp Earnings Call
08/09/23 Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
08/09/23 DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
08/03/23 DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
DRRX Chatroom

User Image Biomd12 Posted - 5 hours ago

$DRRX Totally unacceptable to not even acknowledge the funding issue or discuss how they are thinking about funding a P3. I sent a note to IR mentioning this is totally unacceptable and nothing I've ever seen before from a public company. At least mention it and say "We are exploring all options for funding the p3 trial and will provide additional details as soon as possible."

User Image udupisek Posted - 6 hours ago

$DRRX It appears that the market is reacting positively this AM. FDA will soon give the verdict. Do or die for me . I will hang in. Not selling any.

User Image Biomd12 Posted - 17 hours ago

$DRRX No mention of how they plan to keep the lights on over next 2+ years while they run a phase 3 and burn 100M. Classic.

User Image MissBurns Posted - 18 hours ago

$DRRX if you were on this afternoon’s earnings call. Ask yourself WHY wasn’t Brown able to answer any of the Analyst’s questions regarding the FDA or anything about the next steps. They are a direct conduit / mouthpiece to the market. And yet Brown tried to silence them time and time again this afternoon. With vague answers and dead ends. If you think he’s doing that because he can’t say anything, you’re missing the point. He chose not to because he does not want to be complicit and be put on the spot. He continues to ride a false narrative that everything is fine. It is not fine because they are strapped for cash. They are running on fumes. Instead of aggressively marketing Larsucosterol to a potential successor, Brown continues to regurgitate the same script he’s been reading from the past. The past is over. Ask yourself what can he do NOW to provide shareholder value? I didn’t hear one plan of action today. Did you?

User Image Drrxgernbcrx Posted - 20 hours ago

$DRRX I've around biotechnology long enough to read between the lines. Dr. Brown and more specifically Durect CAN'T say anything due to the repercussions it would have with the powers at hand (FDA). They are at their mercy. It's not what they are saying, it's how they're working to not say it. Delusional, we'll we'll see I guess. I'd say experienced...

User Image doubleyou2 Posted - 21 hours ago

$DRRX ok, till the end of june then for more news... Maybe

User Image DMONEY1337 Posted - 21 hours ago

$DRRX A lot of delusional folks still here. Phase 3 is a given. Brown would be sued to high heaven if FDA now granted accelerated approval. Brown was clear as he could be that a phase 3 is the path forward. Ill watch to see how they plan to fund this thing...

User Image Drrxgernbcrx Posted - 21 hours ago

$DRRX That was actual a GREAT call and here's why: 1. Dr. Brown went out of his way to not reveal ANYTHING in regard to the FDA. In other words, he's kissing the ring and pushing toward accelerated approval. 2. Talks with the FDA are on going. If it was on to phase 3 without consideration for approval, they would have just said that. 3. No talk of downsizing or reducing expenses. In other words, worst case scenario we have funding, financing, or a partnership we'll in hand. 4. No shares were sold thru the ATM to bolster the balance sheet which reinforces #3. There are no guarantees but reading the tea leaves, this was as positive as we could have hoped for....

User Image bnjhnsn Posted - 22 hours ago

$DRRX on a positive note, Tim Papp was on the ball enough to recite the Safe Harbor statement just moments before he lied through his teeth by saying that they had enough funding to get through 2024.

User Image MissBurns Posted - 22 hours ago

$DRRX how on earth can management sit there and say AHFIRM was a success? Did I miss something because when I look at the current stock price it’s saying LOUD and CLEAR that it was a failure? How on earth can Brown sit there and basically have nothing new to share? FDA talks are ongoing…everyone will have to wait another 3 months to maybe get a crumb thrown at them. Another trial? WITH WHAT MONEY?!?!?! Zero mention of a partnership Zero mention of a buy out Don’t tell me anymore about the “potential” Larsucosterol has. It’s dead in the water until someone else can get it far away from Brown.

User Image bigbulldaddy Posted - 22 hours ago

$DRRX I’m taking no news as good news. They have to guide for phase 3 or get sued. They can’t talk that new partnership. We are in a holding pattern for another quarter.

User Image bnjhnsn Posted - 22 hours ago

$DRRX it's been a long, long wait. ...for nothing. They should have simply said that we are not going to host a conference call

User Image brunoq14 Posted - 22 hours ago

$DRRX Hey, enough cash to get through the end of the year!

User Image brunoq14 Posted - 23 hours ago

$DRRX First impression negative. Mentions new Phase 3. No accelerated approval with confirmatory trial. $30M cash, '17M debt.

User Image ld4 Posted - 23 hours ago

$DRRX I know we said we will update you in the 1st quarter after we spoke to the FDA but we spoke to them and its all pretty negative stuff, so I’m going to pretend we’ll update you in the 2nd quarter now.

User Image DMONEY1337 Posted - 23 hours ago

$DRRX Gotta give it to Brown. The man has destroyed 99% of shareholder value over last 20 years and is still milking it for seven figure comp package. Bravo!

User Image epsguid Posted - 23 hours ago

$DRRX reported a loss of $0.27, consensus was ($0.36) via @eWhispers #epsbeat http://eps.sh/d/drrx

User Image DonCorleone77 Posted - 23 hours ago

$DRRX Durect reports Q4 EPS (10c), consensus (33c) Reports Q4 revenue $2.7M, consensus $2.48M. "We remain enthusiastic about the improvement in 90-day mortality demonstrated in our Phase 2b AHFIRM clinical trial and are communicating with the FDA about the design of a confirmatory Phase 3 trial to support the potential approval of larsucosterol as a treatment for alcohol-associated hepatitis," stated James Brown, CEO. "Larsucosterol could be the first FDA-approved treatment to address AH, a highly lethal condition that results in approximately 158,000 hospitalizations in the U.S. annually with a 30% mortality rate at 90 days."

User Image Stock_Titan Posted - 23 hours ago

$DRRX DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/DRRX/durect-corporation-reports-fourth-quarter-and-full-year-2023-1wgl0ti604yn.html

User Image doubleyou2 Posted - 23 hours ago

$DRRX "Dear Shareholders, I wish to thank you for your understanding of the stupid moves i made a while ago, with the direct results : * an implosion of our stock price * a difficult situation to collect the needed cash through offerings * more and difficult conversations are needed and requested by the FDA Meanwhile I had the continuing pleasure of receiving my monthly wage, which isn't so bad. At last I want to stipulate that we, as a company, are on track to realise almost everything we had in mind in the coming years. There are opportunities. There are some conditions too, i have to admit : 1/ the FDA has to give the green light, and 2/ we are in urgently need for some new money. If we get 1/, i'll promise we'll get 2/ too. If there are no more questions, well, that was it for today. Hope to meet again next quarter. Jim Brown. " PS: Not financial advice. Just a bit sarcastic piece.

User Image blucpa Posted - 1 day ago

$DRRX probably a sell here before the news? Will we ever see the 1.30s again?

User Image Biomd12 Posted - 1 day ago

$DRRX Maybe we will get an update on the Oncology program today! Haha. Hopeful Brown announces they are starting the bidding process to sell the company.

User Image DMONEY1337 Posted - 1 day ago

$DRRX Someone needs to ask BiG Jim Bo Brown where the disconnect is... Multi billion dollar market opportunity, promising results and market says its basically worthless. If they can't secure funding and no one wants to buy the asset, something just isn't right here. JB may have played us all.

User Image MissBurns Posted - 2 days ago

$DRRX 2 more days til “We are on track” to disclosing absolutely nothing about our meeting with the FDA. Thus leaving our devoted, long term investors in the dark about what our next course of action will be. But we have this incredible molecule and take a wrecking ball and destroy all shareholder value that is associated with it. - JB 2 more days til you can prove me right or wrong Brown is going to say hardly anything. If history repeats itself he will wait til the last possible second to disclose anything to the general public. Just like he has done historically. Good luck longs. Many of you I still have mad respect for as you are hanging in there. Time will tell of the remaining shares I do have just get blown up with Brown’s inability to throw a Hail Mary in the next few months. It will take a miracle. I’m neither bullish or bearish at this juncture, just indifferent which helps with the constant disappointments.

User Image MissBurns Posted - 5 days ago

$DRRX well at least they are off the NASDAQ no no list…. I can’t wait to hear JB spew some “on track” one liners on next week’s EC Like: We are “on track” to secure a suitable buy out partner. We are “on track” to be unable to get enough financing for p3 We are “on track” to destroying all existing shareholders who have been loyal to us all these years. We are “on track” to let Larscucosterol slip through our fingers time and time again. We are “on track” to keep our existing useless board and upper management who have done nothing to instill shareholder value. If I missed any “on track” bets please feel free to free to add some here… Cocktails anyone? 🍸

User Image bigbulldaddy Posted - 1 week ago

$DRRX so literally nothing till end of March… probably have fda news in hand for that?

User Image Stock_Titan Posted - 1 week ago

$DRRX DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update https://www.stocktitan.net/news/DRRX/durect-corporation-to-announce-fourth-quarter-and-full-year-2023-syl31bgz6gqj.html

User Image bnjhnsn Posted - 1 week ago

$DRRX 91k traded today. Mums the word...

User Image Invest2live Posted - 1 week ago

$DRRX 144% already; congrats 🎊🎈🎉 Check out $BTDR; similar potential

User Image Invest2live Posted - 1 week ago

$DRRX you will prevail; patience

Analyst Ratings
JonesTrading Hold Nov 9, 23
HC Wainwright & Co. Neutral Nov 8, 23
Cantor Fitzgerald Overweight Aug 10, 23
HC Wainwright & Co. Buy Aug 10, 23
Cantor Fitzgerald Overweight May 17, 23
HC Wainwright & Co. Buy May 9, 23
HC Wainwright & Co. Buy Apr 11, 23
JonesTrading Buy Mar 14, 23
HC Wainwright & Co. Buy Mar 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Robertson Judith J. Director Director Aug 18 Buy 0.85 80,943 68,801 356,132 08/22/22
Robertson Judith J. Director Director Aug 17 Buy 0.84 10,189 8,559 275,189 08/19/22
Maderis Gail J Director Director Aug 12 Buy 0.7139 25,204 17,993 200,000 08/12/22
Maderis Gail J Director Director Aug 09 Buy 0.68 174,796 118,861 174,796 08/11/22
Robertson Judith J. Director Director May 26 Buy 0.3938 65,000 25,597 265,000 05/27/22
AZAB MOHAMMAD Director Director May 24 Buy 0.39 30,000 11,700 60,000 05/25/22
Farfel Gail M Director Director May 16 Buy 0.4 55,211 22,084 100,000 05/18/22
AZAB MOHAMMAD Director Director May 16 Buy 0.41 30,000 12,300 30,000 05/18/22
Farfel Gail M Director Director May 11 Buy 0.4 20,700 8,280 44,789 05/13/22
Farfel Gail M Director Director May 10 Buy 0.406 2,339 950 24,089 05/12/22
Farfel Gail M Director Director May 09 Buy 0.39 21,750 8,482 21,750 05/10/22
Joice Judy R Sr. VP Operations &.. Sr. VP Operations & Corp QA May 17 Option 0.76 60,137 45,704 94,969 05/17/21
Joice Judy R Sr. VP Operations &.. Sr. VP Operations & Corp QA May 17 Sell 1.72 60,137 103,436 34,832 05/17/21